CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞受者中的巨细胞病毒感染
英文原题：Cytomegalovirus infection in chimeric antigen receptor T-cell recipients.
查看英文原题
Cytomegalovirus infection in chimeric antigen receptor T-cell recipients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是一种用于血液系统恶性肿瘤的创新免疫治疗方法。使用该疗法的一些挑战包括细胞因子释放综合征、免疫效应细胞相关神经毒性综合征、免疫抑制和低丙种球蛋白血症的发生，这些情况可能持续时间较长，并显著增加患者的感染风险。众所周知，巨细胞病毒（CMV）可在免疫功能低下的宿主中引起疾病和器官损伤，增加死亡率和发病率。我们报告一例64岁多发性骨髓瘤男性患者，有显著的CMV感染史，在接受CAR-T 细胞治疗后病情加重，并因长期血细胞减少、骨髓瘤进展和其他机会性感染的发生而变得难以控制。对于CAR-T 细胞治疗受者中CMV感染的预防、治疗和维持策略，仍有待进一步确立。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy is an innovative immunotherapy treatment for hematological malignancies. Some of the challenges in using this therapy are the development of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immunosuppression, and hypogammaglobulinemia, which can be prolonged and significantly increase patients' risk of infection. Cytomegalovirus (CMV) is well known to cause disease and organ damage in immunocompromised hosts, increasing mortality and morbidity.
We present a case of a 64-year-old man with multiple myeloma with a significant history of CMV infection that worsened after CAR T-cell therapy and became challenging to contain because of prolonged cytopenias, progression of myeloma, and development of other opportunistic infections. Strategies for prophylaxis, treatment, and maintenance of CMV infections in CAR T-cell therapy recipients are further warranted.
论文信息
- 作者
- Abreu M、Varghese J、Santiago M、Ow K
- 第一作者单位
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer, Houston, Texas.United States
- 文献类型
- 病例报告
- 期刊
- Journal of the American Association of Nurse Practitioners2023 Nov 1
- 原文标识
- PubMed 37294946 · DOI 10.1097/JXX.0000000000000903